Medications for Weight Reduction

Endocrinology and Metabolism Clinics of North America

Volumn 37, Issue 4, 2008, Pages 923-942

  Bray, George A ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

Cannabinoid receptor antagonists; Glucagon like peptide analogues; Lipase inhibitor; Sympathomimetic drugs

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; AMFEPRAMONE; ANTIOBESITY AGENT; APD 356; BENZPHETAMINE; BONTRIL PDM; CANNABINOID RECEPTOR ANTAGONIST; CETILISTAT; CP 945598; DOSPAN; EXENDIN 4; FENFLURAMINE; FLUOXETINE; GLUCAGON LIKE PEPTIDE DERIVATIVE; LAMOTRIGINE; LIPASE INHIBITOR; LONAMIN; METFORMIN; NALTREXONE; OBENIX; OBY CAP; OBY TRIM; PHENDIMETRAZINE; PHENDIMETRAZINE TARTRATE; PHENTERMINE; PLACEBO; PRAMLINTIDE; PRELU 2; QNEXA; RIMONABANT; SERTRALINE; SIBUTRAMINE; SULFONYLUREA; TAK 677; TARANABANT; TETRAHYDROLIPSTATIN; THIAZIDE DIURETIC AGENT; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; X TROZINE; ZANTRYL; ZONISAMIDE;

ANXIETY; ASTHENIA; BODY MASS; CARDIOVASCULAR SYMPTOM; CENTRAL NERVOUS SYSTEM; CHRONIC DISEASE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIET RESTRICTION; DIZZINESS; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG SAFETY; ENERGY EXPENDITURE; FECAL FAT LOSS; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; HEALTH HAZARD; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INSOMNIA; INTESTINE BYPASS; LONG TERM CARE; MOOD CHANGE; MORNING DOSAGE; NAUSEA; NONHUMAN; OBESITY; PALLIATIVE THERAPY; PARESTHESIA; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SHORT COURSE THERAPY; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP APNEA SYNDROME; SLOW RELEASE FORMULATION; SOMNOLENCE; TREATMENT RESPONSE; VOMITING; WEIGHT CONTROL; WEIGHT REDUCTION; XEROSTOMIA;

ANIMALS; ANTI-OBESITY AGENTS; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM AGENTS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; EATING; HUMANS; INTESTINAL ABSORPTION; LIPID METABOLISM; OBESITY; WEIGHT LOSS;

EID: 56249146307     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2008.08.004     Document Type: Review

References (88)

1. World Health Organization. Obesity: preventing and managing the global epidemic (1998), World Health Organization, Geneva (Switzerland)
2. NHLBI Obesity Education Initiative Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report. Obes Res 6 Suppl 2 (1998) 51S-209S
3. Ogden C.L., Yanovski S.Z., Carroll M.D., et al. The epidemiology of obesity. Gastroenterology 132 6 (2007) 2087-2102
4. Bray G.A. The metabolic syndrome and obesity (2007), Humana Press, Totowa (NJ)
5. Padwal R., Li S.K., and Lau D.C. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord 27 12 (2003) 1437-1446
6. Shekelle P.G., Hardy M.L., Morton S.C., et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA 289 12 (2003) 1537-1545
7. Li Z., Maglione M., Tu W., et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 142 7 (2005) 532-546
8. Bray G., and Greenway F. Pharmacological treatment of the overweight patient. Pharmacol Rev 59 2 (2007) 151-184
9. Bray G.A., and Greenway F.L. Current and potential drugs for treatment of obesity. Endocr Rev 20 6 (1999) 805-875
10. Bray G.A., and Ryan D.H. Drug treatment of the overweight patient. Gastroenterology 132 6 (2007) 2239-2252
11. Shekelle P.G., Morton S.C., Maglione M., et al. Pharmacological and surgical treatment of obesity. Evid Rep Technol Assess (Summ) 103 (2004) 1-6
12. Avenell A., Brown T.J., McGee M.A., et al. What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions. J Hum Nutr Diet 7 4 (2004) 293-316
13. Smith I.G., and Goulder M.A. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 50 6 (2001) 505-512
14. Apfelbaum M., Vague P., Ziegler O., et al. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 106 2 (1999) 179-184
15. James W.P., Astrup A., Finer N., et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group (Sibutramine Trial of Obesity Reduction and Maintenance). Lancet 356 9248 (2000) 2119-2125
16. Wirth A., and Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 286 11 (2001) 1331-1339
17. McMahon F.G., Fujioka K., Singh B.N., et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 160 14 (2000) 2185-2191
18. Fujioka K., Seaton T.B., Rowe E., et al. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2 3 (2000) 175-187
19. Berkowitz R.I., Wadden T.A., Tershakovec A.M., et al. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA 289 14 (2003) 1805-1812
20. Godoy-Matos A., Carraro L., Vieira A., et al. Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study. J Clin Endocrinol Metab 90 3 (2005) 1460-1465
21. Berkowitz R.I., Fujioka K., Daniels S.R., et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Ann Intern Med 145 2 (2006) 81-90
22. Daniels S.R., Arnett D.K., Eckel R.H., et al. Overweight in children and adolescents: pathophysiology, consequences, prevention, and treatment. Circulation 111 15 (2005) 1999-2012
23. Wadden T.A., Berkowitz R.I., Womble L.G., et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 353 20 (2005) 2111-2120
24. Sjostrom L., Rissanen A., Andersen T., et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients: European Multicentre Orlistat Study Group. Lancet 352 9123 (1998) 167-172
25. Torgerson J.S., Hauptman J., Boldrin M.N., et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27 1 (2004) 155-161
26. Chanoine J.P., Hampl S., Jensen C., et al. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 293 23 (2005) 2873-2883
27. Hollander P.A., Elbein S.C., Hirsch I.B., et al. Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blind study. Diabetes Care 21 8 (1998) 1288-1294
28. Kelley D.E., Bray G.A., Pi-Sunyer F.X., et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 25 6 (2002) 1033-1041
29. Miles J.M., Leiter L., Hollander P., et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 25 7 (2002) 1123-1128
30. Heymsfield S.B., Segal K.R., Hauptman J., et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 160 9 (2000) 1321-1326
31. Zhi J., Mulligan T.E., and Hauptman J.B. Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients. J Clin Pharmacol 39 1 (1999) 41-46
32. Wadden T.A., Berkowitz R.I., Womble L.G., et al. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes Res 8 6 (2000) 431-437
33. Lawton C.L., Wales J.K., Hill A.J., et al. Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects. Obes Res 3 4 (1995) 345-356
34. Goldstein D.J., Rampey Jr. A.H., Roback P.J., et al. Efficacy and safety of long-term fluoxetine treatment of obesity: maximizing success. Obes Res 4 Suppl 3 (1995) 481S-490S
35. Gadde K.M., Parker C.B., Maner L.G., et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res 9 9 (2001) 544-551
36. Jain A.K., Kaplan R.A., Gadde K.M., et al. Bupropion SR vs placebo for weight loss in obese patients with depressive symptoms. Obes Res 10 10 (2002) 1049-1056
37. Anderson J.W., Greenway F.L., Fujioka K., et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res 10 7 (2002) 633-641
38. Astrup A., and Toubro S. Topiramate: a new potential pharmacological treatment for obesity. Obes Res 12 Suppl (2004) 167S-173S
39. Ben-Menachem E., Axelsen M., Johanson E.H., et al. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res 11 4 (2003) 556-562
40. Bray G.A., Hollander P., Klein S., et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 11 6 (2003) 722-733
41. Wilding J., Van Gaal L., Rissanen A., et al. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord 28 11 (2004) 1399-1410
42. Astrup A., Caterson I., Zelissen P., et al. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes Res 12 10 (2004) 1658-1669
43. Gadde K.M., Franciscy D.M., Wagner II H.R., et al. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 289 14 (2003) 1820-1825
44. Devinsky O., Vuong A., Hammer A., et al. Stable weight during lamotrigine therapy: a review of 32 studies. Neurology 54 4 (2000) 973-975
45. Merideth C.H. A single-center, double-blind, placebo-controlled evaluation of lamotrigine in the treatment of obesity in adults. J Clin Psychiatry 67 2 (2006) 258-262
46. Fontbonne A., Charles M.A., Juhan-Vague I., et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution: BIGPRO study group. Diabetes Care 19 9 (1996) 920-926
47. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 6 (2002) 393-403
48. Ortega-Gonzalez C., Luna S., Hernandez L., et al. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab 90 3 (2005) 1360-1365
49. Riddle M.C., and Drucker D.J. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care 29 2 (2006) 435-449
50. Ratner R.E., Dickey R., Fineman M., et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med 21 11 (2004) 1204-1212
51. Maggs D., Shen L., Strobel S., et al. Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis. Metabolism 52 12 (2003) 1638-1642
52. Patriti A., Facchiano E., Sanna A., et al. The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery. Obes Surg 14 6 (2004) 840-848
53. Small C.J., and Bloom S.R. Gut hormones as peripheral anti-obesity targets. Curr Drug Targets CNS Neurol Disord 3 5 (2004) 379-388
54. Greenway S.E., Greenway III F.L., and Klein S. Effects of obesity surgery on non-insulin-dependent diabetes mellitus. Arch Surg 137 10 (2002) 1109-1117
55. Lugari R., Dei Cas A., Ugolotti D., et al. Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion. Horm Metab Res 36 2 (2004) 111-115
56. Szayna M., Doyle M.E., Betkey J.A., et al. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 141 6 (2000) 1936-1941
57. Gedulin B.R., Nikoulina S.E., Smith P.A., et al. Exenatide (exendin-4) improves insulin sensitivity and beta-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 146 4 (2005) 2069-2076
58. Rodriquez de Fonseca F., Navarro M., Alvarez E., et al. Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. Metabolism 49 6 (2000) 709-717
59. Kastin A.J., and Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord 27 3 (2003) 313-318
60. Edwards C.M., Stanley S.A., Davis R., et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 281 1 (2001) E155-E161
61. Fineman M.S., Shen L.Z., Taylor K., et al. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev 20 5 (2004) 411-417
62. DeFronzo R.A., Ratner R.E., Han J., et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28 5 (2005) 1092-1100
63. Kendall D.M., Riddle M.C., Rosenstock J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28 5 (2005) 1083-1091
64. Buse J.B., Henry R.R., Han J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27 11 (2004) 2628-2635
65. Heine R.J., Van Gaal L.F., Johns D., et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 143 8 (2005) 559-569
66. Van Gaal L.F., Rissanen A.M., Scheen A.J., et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365 9468 (2005) 1389-1397
67. Despres J.P., Golay A., and Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353 20 (2005) 2121-2134
68. Pi-Sunyer F.X., Aronne L.J., Heshmati H.M., et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. RIO-North America: a randomized controlled trial. JAMA 295 7 (2006) 761-775
69. Scheen A.J., Finer N., Hollander P., et al. RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomized controlled study. Lancet 368 (2006) 1660-1672
70. Parker E., Van Heek M., and Stamford A. Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status. Eur J Pharmacol 440 2-3 (2002) 173-187
71. Erondu N., Gantz I., Musser B., et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab 4 4 (2006) 275-282
72. Erondu N., Wadden T., Gantz I., et al. Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss. Obesity (Silver Spring) 15 4 (2007) 895-905
73. Gibson W.T., Ebersole B.J., Bhattacharyya S., et al. Mutational analysis of the serotonin receptor 5-HT2C in severe early-onset human obesity. Can J Physiol Pharmacol 82 6 (2004) 426-429
74. Nilsson B.M. 5-Hydroxytryptamine 2C (5-HT2C) receptor agonists as potential antiobesity agents. J Med Chem 49 14 (2006) 4023-4034
75. Cangiano C., Ceci F., Cascino A., et al. Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan. Am J Clin Nutr 56 5 (1992) 863-867
76. Cangiano C., Laviano A., Del Ben M., et al. Effects of oral 5-hydroxy-tryptophan on energy intake and macronutrient selection in non-insulin-dependent diabetic patients. Int J Obes Relat Metab Disord 22 7 (1998) 648-654
77. Rogers P.J., and Blundell J.E. Effect of anorexic drugs on food intake and the micro-structure of eating in human subjects. Psychopharmacology (Berl) 66 2 (1979) 159-165
78. Foltin R.W., Haney M., Comer S.D., et al. Effect of fenfluramine on food intake, mood, and performance of humans living in a residential laboratory. Physiol Behav 59 2 (1996) 295-305
79. Drent M.L., Zelissen P.M., Koppeschaar H.P., et al. The effect of dexfenfluramine on eating habits in a Dutch ambulatory android overweight population with an overconsumption of snacks. Int J Obes Relat Metab Disord 19 5 (1995) 299-304
80. Walsh A.E., Smith K.A., Oldman A.D., et al. m-Chlorophenylpiperazine decreases food intake in a test meal. Psychopharmacology (Berl) 116 (1994) 120-122
81. Boeles S., Williams C., Campling G.M., et al. Sumatriptan decreases food intake and increases plasma growth hormone in healthy women. Psychopharmacology (Berl) 129 2 (1997) 179-182
82. Smith S.R., Prosser W., Donahue D., et al. APD356, an orally-active selective 5-HT2C agonist reduces body weight in obese men and women. Diabetes Metab 55 Suppl 1 (2006) A80
83. Dunk C., Enunwa M., De La Monte S., et al. Increased fecal fat excretion in normal volunteers treated with lipase inhibitor ATL-962. Int J Obes Relat Metab Disord 26 Suppl (2002) S135
84. Kopelman P., Bryson A., Hickling R., et al. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes (Lond) 31 3 (2007) 494-499
85. Weintraub M. Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study. Clin Pharmacol Ther 51 5 (1992) 581-585
86. Stafford R.S., and Radley D.C. National trends in antiobesity medication use. Arch Intern Med 163 9 (2003) 1046-1050
87. Connolly H.M., Crary J.L., McGoon M.D., et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337 9 (1997) 581-588
88. Redman L.M., de Jonge L., Fang X., et al. Lack of an effect of a novel beta-3-adrenoceptor agonist, TAK-677, on energy metabolism in obese individuals: a double-blind, placebo-controlled randomized study. J Clin Endocrinol Metab 92 2 (2007) 527-531